) Meropenem Chemotherapy (Tokyo) ) panipenem/betamipron Chemotherapy (Tokyo) ) Meropenem Chemotherapy (Toky
|
|
|
- えの みうら
- 5 years ago
- Views:
Transcription
1 ) ) UTI ( )UTI ( 3 )Chemotherapy (Tokyo) ) () ) ) ) Chemotherapy (Tokyo) ) Imipenem/Cilastatin sodium (MK-0787/MK-0791) Chemotherapy (Tokyo) : ) Meropenem Chemotherapy (Tokyo) 1992; ) Meropenem Chemotherapy (Tokyo) 1992 ; ) Imipenem/Cilastatin sodium (MK- 0787/MK-0791) Chemotherapy (Tokyo) ) Panipenem/Betamipron Jpn J antibiotics ) Meropenem Jpn J Antibiotics ) Panipenem/betamipron (CS-976) ) Meropenem Chemotherapy (Tokyo) ) Panipenem/Betamipron Jpn J Antibiotics ) Meropenem Chemotherapy (Tokyo) ) panipenem/betamipron Chemotherapy (Tokyo)
2 ) Meropenem Chemotherapy (Tokyo) ) panipenem/betamipron Chemotherapy (Tokyo) ) Meropenem Chemotherapy (Tokyo) ) Meropenem Chemotherapy (Tokyo) ) Imipenem/Cilastatin sodium (MK-0787/MK-0791) Chemotherapy (Tokyo) ) MK-0787/MK-0791 Piperacillin ) panipenem/betamipron imipenem/cilastatin Chemotherapy (Tokyo) ) panipenem/betamipron imipenem/cilastatin Chemotherapy (Tokyo) ) meropenem imipenem/cilastatin sodium Chemotherapy (Tokyo) ) meropenem imipenem/cilastatin sodium Chemotherapy (Tokyo) ) biapenem imipenem/cilastatin ) biapenem imipenem/cilastatin ) biapenem imipenem/cilastatin ) 2)
3 2.7 32) 1) ) UTI ( )UTI ( 3 ) Chemotherapy (Tokyo) ) Meropenem ) Meropenem ) ) Knaus WA, Draper EA, Wagner DP, Zimmerman JEAPACHEA severity of disease classification systemcritical Care Medicine ) Cometta A, Baumgartner JD, Lew D, Zimmerli W, Pittet D, Chopart P et alprospective randomized comparison of imipenem monotherapy with imipenem plus netilmicin for treatment of severe infections in nonneutropenic patientsantimicrob Agents Chemother 1994June ) Beaucaire GClinical activity of cefepime in severe infectionsclin Microbiol Infect S6-S14 40) M.P.Fink, D.R.Snydman, M.S.Niderman, K.V.Leeper,Jr., R.H.Johnson, S.O.Heard et al. Treatment of severe pneumonia in hospitalized patients: Results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. Antimicrob. Agents Chemother ) F.A.Lerma, on behalf of the serious infection study group. Efficacy of meropenem as monotherapy in the treatment of ventilator-associated pneumonia. J. Chemother ; 13 : ) 2002
4 Report ( 1) R mg 50 mg125 mg 250 mg500 mg R mg 250 mg500 mg 1000 mg R mg 1 2 R mg 1 2 R mg mg 1 3 Report Report (11 ) 6 (11 ) 1 (3 ) Report Report Report05 R142G R142H R143P R143Q R143S ( ) ( ) ( ) ( ) ( ) ( ) ( ) R143T R143V R143W ( ) mg500 mg mg mg mg mg mg mg mg Report Report Report Report Report Report Report13
5 ( 2) Report03Report06 R1415 R1418 R1416 R142R R142U R143R R143U R142A R142C ( ) ( ) R142D ( ) mg mg mg mg500 mg mg500 mg mg 1 2 (MEPM) 500 mg mg 1 2 (MEPM) 500 mg Report mg mg mg mg mg mg mg mg mg mg Report Report Report Report Report Report Report07
6 ( 3) Report16 R142E ( ) R142F R143J R143K R143L R143M ( ) ( ) ( ) ( ) ( ) R143N ( ) R143E ( ) R143A [ ( )] R1431 ( ) mg mg mg mg mg mg mg mg mg mg mg mg mg mg mg mg mg mg mg mg mg mg mg mg mg mg mg ( 28 ) Report Report Report Report Report Report Report Report Report17
7 () Report mg () LD mg/kg 1/600 () mg/kg 1/ mg 1/ DRPM ( mg60 ) mg 2 ( kg) DRPM DRPM mg 1 1 (60 ) (250 mg) (500 mg) ( ) ( ) (ASTALTAl-PLAPLDHγ-GTP A/G TTTZTTBUN NaKClCaPβ 2 -) (α 1 -β 2 -NAGNa KClpH ) ( ) () () * 19 () 19 () *
8 (hr) DRPM (60 ) 12 ph a) b) c) d) (60 ) a) 500 mg b) 125 mg250 mg500 mg c) 2(810hr1012hr) d) 12 (1224hr)
9 2.7 1) () 1 () ) 10 ALT 1 7 DRPM 3) DRPM 25 mg50 mg125 mg250 mg500 mg ( 2 ) 60 Cmax AUC 2- t 1/2 (β) 1 70%( ) 4) 500 mg DRPM TLC- DRPM
10 2.7 5) 250 mg 1 1 ALT DRPM 7 DRPM 500 mg Cmax AUC DRPM 70% DRPM ( )
11 () Report DRPM mg ( mg30 ) mg 6 ( kg) DRPM DRPM mg 1 1 (30 ) (250 mg) (500 mg) ( ) ( ) (ASTALTAl-PLAPLDHγ-GTP A/G TTTZTTBUN NaKClCaPβ 2 -) (α 1 -β 2 -NAGNa KClpH ) ( ) () () * 19 () 19 () *
12 (hr) DRPM (30 ) 12 ph a) 24hr b) c) DRPM (30 ) a) 500 mg1000 mg b) 2 (810hr1012hr) c)12 (1224hr)
13 2.7 1) () 1 () ) 24 3 (γ-gtp AST ) DRPM 3) DRPM mg 30 Cmax AUC t 1/2 (β) 24 DRPM 1000 mg 24 DRPM 75%DRPM (DRPM-DC) 90% ( ) 4) DRPM 1000 mg DRPM TLC-
14 2.7 DRPM 5) DRPM DRPM-DC HPLC 24 () 125 mg 12.7%250 mg 12.1%500 mg 15.5%1000 mg 17.2% ( ) DRPM-DC AUC AUC 250 mg 4%500 mg 6%1000 mg 7% 125 mg DRPM-DC DRPM-DC Cmax Cmax 250 mg 3% 500 mg 3% 1000 mg 4%DRPM DRPM-DC 24 90% ( ) 6) ex vivo % ( ) 7) DRPM 1000 mg Cmax AUC 125 mg 1000 mg () 125 mg 1000 mg 24 75% DRPM DRPM-DC AUC AUC 250 mg 4%500 mg 6%1000 mg 7%DRPM-DC Cmax Cmax 250 mg 3% 500 mg 3% 1000 mg 4% (DRPM) DRPM-DC 90% mg ( 30 2 ) % DRPM mg 125 mg 1000 mg
15 () Report DRPM500 mg ( ) (1 500 mg ) 8 ( 2 ) ( kg) DRPM DRPM 500 mg 1 2 (30 ) 6 (11 ) ( ) ( ) (ASTALTAl-PLAPLDHγ-GTP A/G TTTZTTBUN NaKClCaPβ 2 -) (α 1 -β 2 -NAGNa KClpH )( ) () () () * 19 () 19 () *
16 DRPM (30 ) 12 ph () DRPM (30 ) *
17 1) () 1 () ) DRPM 500 mg ( 11 ) (30 ) DRPM 1 () DRPM 3) DRPM DRPM EnterobacteriaceaeLactobacillus Streptococcus Enterococcus 7 C. difficile DRPM 1 4
18 () No. of aerobes (log CFU/g of feces) Isolate Enterobacteriaceae GNF-GNR a) Streptococcus Enterococcus Staphylococcus Bacillus Yeasts Lactobacillus 7.1 ND b) ND ND ND Total aerobes a) b)not detected () No. of anaerobes (log CFU/g of feces) Isolate Bacteroides Fusobacterium Bifidobacterium Eubacterium Lactobacillus Clostridium Peptococcaceae Veillonellaceae ND a) Total anaerobes a)not detected 4) DRPM DRPM Streptococcus HaemophilusNeisseriaceae Bacteroides FusobacteriumActinomycesStreptococcusVeillonella 3 6
19 () Isolate Enterobacteriaceae GNF-GNR c) Haemophilus Streptococcus Staphylococcus Neisseriaceae Bacillus Corynebacterium Yeast Lactobacillus ND b) ND a) ND ND No. of aerobes (log CFU/swab) 3 ND ND ND ND ND 1.2 ND ND ND ND ND ND 4.5 ND 3.0 Total aerobes a) b)not detected c) () Bacteroides Fusobacterium Actinomyces Bifidobacterium Propionibacterium Eubacterium Peptostreptococcus Streptococcus Veillonella Isolate ND b) No. of anaerobes (log CFU/swab) a) ND ND ND ND ND ND 3.7 ND ND ND Total anaerobes a) b)not detected 5) DRPM 500 mg ( ) 30 DRPM ( ) 6) 500 mg % ( )
20 7) β- 3 1 DRPM DRPM (0.15 µg/g) ( ) β ( ) DRPM Fecal concentraions (µg/g) Before Day 3 Day 7 ( 1 ) 1 <0.15 <0.15 < <0.15 <0.15 < <0.15 <0.15 < <0.15 <0.15 < a) <0.15 <0.15 < <0.15 <0.15 < a) <0.15 <0.15 < <0.15 <0.15 <0.15 a)placebo DRPM β lactamase β lactamase activity Before Day 3 Day 7 ( 1 ) a) a) ) β lactamase Nitrocefin (2E-n) a)placebo 8) Cmax 12 DRPM 2
21 () Report DRPM1000 mg ( mg ) 8 ( 2 ) ( kg) DRPM DRPM 1000 mg 1 2 (30 ) 6 (11 ) (500 mg) () ( ) ( ) (ASTALTAl-PLAPLDHγ-GTP A/G TTTZTTBUN NaKClCaPβ 2 -) (α 1 -β 2 -NAGNa KClpH ) (CRP ) () * 19 () 19 () *
22 DRPM CRP ph () () β
23 1) () 2 () ) DRPM 1 DRPM DRPM AST ALT 1 ALT 1 ALT LDH 1 3 DRPM DRPM DRPM
24 3) DRPM Enterobacteriaceae Enterococcus 7 BacteroidesBifidobacterium C. difficile DRPM mg 1 2 4) DRPM 1000 mg ( ) 30 DRPM ( ) 5) 1000 mg % ( ) 6) β- DRPM ( 34 ) ( 67 ) (0.15 µg/g) β- 7) DRPM ( mg 1 2 )
25 (500 mg 3 ) Report DRPM mg DRPM (1 500 mg ) 6 ( kg) DRPM DRPM 500 mg 1 3 (30 ) 3 (500 mg) () () ( ) (ASTALTAl-PLAPLDHγ-GTP BUNNaKCl) ( )(CRP) () * 20 () 20 () *
26 2 1 1 () 1 7 () () )
27 () ) DRPM 500 mg 1 3 (6 3 ) 30 () () DRPM ( ) 3) 2 ( 4 ) DRPM 1 [ ()] 4) 1 3 DRPM
28 () Report DRPM 2 ( 250 mg 500 mg3060 ) () 13 () 12 1) ) 2) 3) β- 4) 5) DRPM 6) 6 7) DRPM DRPM mg () 500 mg () (3060 ) 250 mg 500 mg 1) 2) 3) 4) DRPM 1 2 Bioassay 1) 5) ()
29 () () 6) () * 4 19 () 19 () * 1) ( ) 1 () ( 1) () ( 1) () ( 1 1)
30 2.7 2) 項目カテゴリー例数 性 13 年齢 () 69.9 () 4.9 () 61.0 () 72.0 () 75.0 体重 40 kg 50 kg 1 50 kg 60 kg 6 60 kg 70 kg 6 (kg) 59.2 (kg) 6.3 (kg) 46.0 (kg) 59.0 (kg) 69.5 性 13 入院 外来の区分 13 0 基礎疾患の有無 11 2 合併症の有無 13 0 治験薬投与直前の化学療法の有無 ) DRPM 250 mg µg/g (8 ) µg/ml (8 ) % % (7 ) DRPM 500 mg µg/g (5 ) µg/ml (5 ) % (5 ) ( ) 4) A) () () 13 1 () 250 mg 8 500
31 2.7 mg 5 13 B) () () 12 2 () mg mg ( 25.0%)10 () 250 mg 1 ( 8.3%)4 () AST ALT γ-gtp β 2 5) DRPM 250 mg 500 mg )
32 () Report DRPM ( 250 mg30 ) 13 (10 3 ) () 13 () ) 2) () 1) 2) β- 3) 4) 5) 6) 6 (DRPM ) 7) (HIV) 8) () DRPM DRPM mg () (30 ) 250 mg 1) 2) 3) 4) 1) ) () Bioassay
33 () () 1) 5) () 6) () * 19 () 19 () * 1) 13 ( ) () 13 ()
34 2.7 2) () 52.0 () 10.5 () 37.0 () 50.0 () kg 50 kg 3 50 kg 60 kg 6 60 kg 70 kg 4 (kg) 54.7 (kg) 7.6 (kg) 40.0 (kg) 56.0 (kg) 65.0 入院 外来の区分 ) DRPM 250 mg ( 8 ) µg/g (7 ) µg/g (7 ) µg/g (7 ) µg/g (8 ) µg/g (7 ) µg/g (7 ) () µg/ml (10 ) () % (7 ) % (7 ) % (7 ) % (8 ) % (7 ) % (7 )
35 2.7 () 1 µg/ml µg/ml (10 ) () % (10 ) ( ) DRPM 250 mg 30 (3 ) µg/ml 1 (Cmax) µg/ml ( ) %( ) 4) A) () 13 B) () 13 5) DRPM 250 mg )
36 () Report DRPM ( 250 mg30 ) () 10 () 10 () () 1) ) 3) 1) AST 100 IU/L ALT 100 IU/L 2) 3) 4) β- 5) 6) 7) DRPM 8) 6 9) DRPM DRPM mg () (30 ) 250 mg 1) 2) 3) 4) 1 2 Bioassay 1) 5)
37 () () 12 3 () 6) () * 5 20 () 20 () * 1) ( ) () () () () () ()
38 2.7 2) 項目 カテゴリー 例数 性 男 4 女 6 年齢 30 歳以上 40 歳未満 () 64.7 () 16.1 () 35.0 () 69.0 () 79.0 体重 40 kg 1 40 kg50 kg 1 50 kg60 kg 4 60 kg70 kg 4 (kg) 56.3 (kg) 9.7 (kg) 38.5 (kg) 57.5 (kg) 68.0 入院 外来の区分 入院 10 外来 0 基礎疾患 合併症の有無 無 7 有 3 7 無 10 有 0 3) DRPM 250 mg µg/ml (7 ) µg/g (9 ) µg/g (8 ) µg/g (4 ) µg/ml (9 ) 26.5% (1 ) % (5 ) % (5 ) % (3 ) 1 ( )
39 2.7 4) () () 10 1 A) () 10 3 (30.0%)6 3 1 () B) () 10 6 ( 60.0%)13 AST ALT () 5) DRPM 250 mg )
40 () Report DRPM ( 250 mg30 ) () 12 () 12 1) ) 3) 1) AST 100 IU/L ALT 100 IU/L 2) 3) 4) β- 5) 6) 7) DRPM 8) 6 9) DRPM DRPM mg () (30 ) 250 mg 1) 2) 3) 4) 1 2 Bioassay
41 () () 1) 5) () 6) () * 4 20 () 20 () * 1) 12 ( ) () 12 ()
42 2.7 2) () 42.1 () 14.3 () 21.0 () 40.0 () kg 1 40kg50kg 1 50kg60kg 3 60kg70kg 4 70kg 2 1 (kg) 62.7 (kg) 15.7 (kg) 38.0 (kg) 61.7 (kg) 93.6 入院 外来の区分 ) DRPM 250 mg µg/g (5) µg/ml (6 ) % (5 ) µg/g (6 ) µg/ml (6 ) % (6 ) ( ) 4) A) () 12 1 (8.3%)1 ()
43 2.7 () B) () 12 5) DRPM 250 mg )
44 () Report DRPM ( 250 mg30 ) () 10 () 10 1) ) 1) AST 100 IU/L ALT 100 IU/L 2) 3) 4) β- 5) 6) 7) DRPM 8) 6 9) DRPM DRPM mg () (30 ) 250 mg 1) 2) 3) 4) 1 2 Bioassay HPLC
45 () () 1) 5) () 6) () * 20 () 20 () * 1) 10 ( ) () 10 ()
46 2.7 2) () 35.9 () 14.2 () 22.0 () 31.5 () kg 70kg 2 70kg 80kg 1 7 (kg) 65.7 (kg) 8.1 (kg) 60.0 (kg) 62.0 (kg) 75.0 入院 外来の区分 ) DRPM 250 mg µg/g (7 ) µg/ml (10 ) % (7 ) ( ) 4) A) () 10 B) () 10 2 ( 20.0%)2
47 2.7 () BUN () 5) DRPM 250 mg )
48 () Report DRPM () ( 250 mg30 ) () 5 () 5 1) ) 1) AST 100 IU/L ALT 100 IU/L 2) 3) 4) β- 5) 6) 7) DRPM 8) 6 9) DRPM DRPM mg () (30 ) 250 mg 1) 2) 3) 4) 12 Bioassay 1) 5)
49 () () * 12 3 () 6) () 20 () 20 () * 1) 5 ( ) () 5 ()
50 2.7 2) () 67.4 () 9.8 () 52.0 () 70.0 () kg 50kg 1 50kg 60kg 3 60kg 70kg 1 (kg) 56.3 (kg) 5.1 (kg) 49.5 (kg) 56.0 (kg) 63.0 入院 外来の区分 ) DRPM 250 mg µg/ml (5 ) µg/ml (5 ) % (4 ) ( ) 4) A) () 5 1 (20.0%)1 () B) () 5 2 ( 40.0%)2
51 2.7 () 5) DRPM 250 mg )
52 () Report DRPM ( 250 mg30 ) () 10 () 10 () 1) ) 1) AST 100 IU/L ALT 100 IU/L 2) 3) 4) β- 5) 6) 7) DRPM 8) 6 9) DRPM DRPM mg () (30 ) 250 mg 1) 2) 3) 4) 1 2 Bioassay
53 () () 1) 5) () 6) () * 20 () 20 () * 1) 10 ( ) () 10 ()
54 2.7 2) () 29.7 () 9.6 () 20.0 () 26.5 () kg50kg 4 50kg60kg 3 60kg70kg 3 (kg) 53.3 (kg) 9.6 (kg) 40.0 (kg) 51.5 (kg) 68.0 入院 外来の区分 ) DRPM 250 mg µg/g (7 ) µg/ml (6 ) % (6 ) µg/g (3 ) µg/ml (3 ) % (3 ) ( ) 4) A) () 10 B) () 10 4 ( 40.0%)4
55 2.7 () 3 ( 30.0%) ) DRPM 250 mg )
56 () Report DRPM ( 250 mg30 ) () 5 () 3 1) ) 3) 1) AST 100 IU/L ALT 100 IU/L 2) 3) 4) β- 5) 6) 7) DRPM 8) 6 9) DRPM DRPM mg () (30 ) 250 mg 1) 2) 3) 4) 30 ( ) HPLC 1) 5) ()
57 () () 6) () * 2 20 () 20 () * 1) 6 1 ( ) () 5 () ( 1 1)
58 2.7 2) () 59.4 () 15.1 () 38.0 () 63.0 () kg 1 40kg 50kg 1 50kg 60kg 2 60kg 70kg 0 70kg 80kg 1 (kg) 53.8 (kg) 13.5 (kg) 37.0 (kg) 53.0 (kg) 73.0 入院 外来の区分 ) DRPM 250 mg µg/ml (5 ) ( Cmax) µg/ml (5 ) ( ) % (5 ) ( ) 4) A) () 5 B) () () (4 )
59 2.7 AST ALT 1 () 5) DRPM 250 mg )
60 Report DRPM mg ( 250 mg30 ) 6 65 ( kg) DRPM DRPM 250 mg 1 1 (30 ) 250 mg () ( ) (ASTALTAl-PLAPLDHγ-GTP BUNNaKCl ( ) (CRP) () * 20 () 20 () *
61 2.7 () (hr) a) a) b) c) b) 0.5 a)b)c) )
62 2.7 7 () 1 () ) ( 250 mg) ( ) 3) 1 4 () 1 () 12 4) DRPM 8 4 ( ) 1 () 12 ()
63 Report DRPM () 12 () 12 1) ) 3) 4) 70 ml/min 1) 2) 3) 4) 5) β- 6) 7) 8) DRPM 9) 6 10) DRPM DRPM mg () (30 ) 250 mg 1) 2) 3) 4) 1) 30 () ) () Bioassay HPLC 1) 5) 3 5
64 () () * () 6) () 1) AUCCmaxt 1/2 2) 20 () 20 () * 1) 12 ( ) () 12 ()
65 2.7 2) DRPM ( 250 mg) (CLcr) AUC ( ) 3) 8.3% (1/12 ) 1 4) DRPM 250 mg DRPM DRPM 250 mg
日本化学療法学会雑誌第57巻第S-2号
µ µ Key words µ µ µ I Table1. Subjectprofilesin(A)singleand(B)multiple-dosestudies (A)Single-dosestudy Age (yr) Height (cm) Bodyweight (kg) BMI (kg/m ) Ccr(Cockcroft) (ml/min) Ethnicity dose(mg) n 5 5.1±.,3
2.7 臨床概要
2.7 臨床概要 A/G Al-P ALT AST AT- AUC AZM BIPM BP BUN CEZ CFPN-PI CFU CLcr Cmax CNS COPD CPFX CRP CS CYP CVA DBT DHP-I DIC DRPM DRPM-DC FAS γ-gtp GCP GNB GNF-GNR GPB HAM - Staphylococcus C P450 -I Full Analysis
VOL.36 S-I CHEMOTHERAPY Tabl 1 List of healthy male volunteers
VOL.36 S-I CHEMOTHERAPY Tabl 1 List of healthy male volunteers CHEMOTHERAPY MAY 1988 Table 2 Experimental schedule of CS-807 administration and sampling of feces Table 3 Isolation of aerobic and anaerobic
特殊病態下感染症における抗菌薬治験の手引き作成委員会報告書（案）
VOL.51 NO.6 JUNE 2003 JUNE 2003 9) Niederman MS et al: Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy and prevention.
37, 9-14, 2017 : cefcapene piperacillin 3 CT Clostridium difficile CD vancomycin CD 7 Clostridium difficile CD CD associate
37, 9-14, 2017 : 36 2015 8 6 cefcapene piperacillin 3 CT Clostridium difficile CD vancomycin 20 1983 2016 3 CD 7 Clostridium difficile CD CD associated diarrhea : CDAD CD 1,2 PPI 3 1 36 33 2015 8 6 5 5
400 46 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 Dec. 2012 LVFX 100 mg 3 / 7 150 mg 2 / 7 2 2006 2008 9 LVFX PK PD 2009 7 100 mg 1 3 500 mg 1 1 AUC/MIC
Dec. 2012 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 399 45 2012 11 5 LVFX 500 mg 1 1 20 Chlamydia trachomatis C. trachomatismycoplasma genitalium M. genitalium LVFX 1 500 mg 1 1 7 22 22 C. trachomatis 17
CHEMOTHERAPY APRIL 1992 Table 2. Concentration of meropenem in human prostatic fluid Table 1. Background of 21 chronic complicated UTI cases * NB + BPH, NB + Kidney tumor, NB + Kidney tuberculosis Table
日本化学療法学会雑誌第53巻第S-3号
moxifloxacin in vitro moxifloxacin in vitro 17 9 6 17 11 21 moxifloxacinmflx in vitro cefdinir CFDNclavulanic acidamoxicillincvaampcclarithromycincamclindamycincldm levofloxacinlvfx 1MFLX Clostridium clostridiiformeclostridium
1 見出し1，12ポ，日本語ゴシック，英語Arial，段落後は6ポの設定です
8. Page1 8. B 1 5) 6) 2099 2370 50 400 mg 19 (1) 1) (a) 78.9% 30/38 4 3 35.7% 5/14 71.4% 10/1485.7% 12/142 1 83.3% 5/63 2 1 1 1 8. Page2 (b) 2099 1897 82.4% 1562/1897 2 84.0% 1298/1545 3 2 80.4% 472/58779.0%
CHEMOTHERAPY
CHEMOTHERAPY VOL.41 S-2 Laboratory and clinical evaluation of teicoplanin CHEMOTHERAPY AUG. 1993 VOL.41 S-2 Laboratory and clinical evaluation of teicoplanin Table 1. Comparative in vitro activity of teicoplanin
日本化学療法学会雑誌第64巻第4号
β β Moraxella catarrhalisescherichia colicitrobacter Klebsiella pneumoniaeenterobacter cloacaeserratia marcescens Proteus Providencia Pseudomonas aeruginosaacinetobacter Bacteroides fragilis β β E. colik.
CHEMOTHERAPY DEC Table 1 Antibacterial spectra of T-1982, CTT, CMZ, CTX, CPZ and CEZ 106 CFU/ml Note: P; Peptococcus, S; Streptococcus, G; Gaffk
VOL. 30 S-3 CHEMOTHERAPY imeumoniae, Serratia marcescens, Proteus sp, CHEMOTHERAPY DEC. 1982 Table 1 Antibacterial spectra of T-1982, CTT, CMZ, CTX, CPZ and CEZ 106 CFU/ml Note: P; Peptococcus, S; Streptococcus,
50mg 75mg (1) H 3 C O OH HO H O O H OH SO H 3 Na H H N H 2 N NH OH H N O O H H O OH H 3 C H O O N H H H HO H NH CH 3 HN HO H OH O H OH H NH
3240 14 8 8 50mg 75mg 13 6 25 1-(1) H 3 C O OH HO H O O H OH SO H 3 Na H H N H 2 N NH OH H N O O H H O OH H 3 C H O O N H H H HO H NH CH 3 HN HO H OH O H OH H NH O N O C 56 H 70 N 9 NaO 23 S 1292.26 5-[(1S,2S)-2-
Table 1.Quality control of MICs for reference strains Table 2.Antimicrobial activity of gatifloxacin against aerobic bacteria Table 4.Antimicrobial activity of gatifloxacin and other quinolones against
研修コーナー
l l l l l l l l l l l α α β l µ l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l
sick contact1l
Clinical Question 2017 年 5 月 15 日 分野 : 内分泌テーマ : 治療 19 14 15 18 sick contact1l 170cm/68.8kg, GCSE1V1M5, HR: 120/min, BP: 104/60mmHg, RR: 30/min, SpO 2 : 96%, BT: 38.0 WBC Hb PLT CRP Cr BUN 23400 15.0 35.5
日本化学療法学会雑誌第51巻第2号
piperacillin piperacillin PIPC. g Cmax CL PIPC CL CLR CLNR CL PIPC g g Cmax PIPC Key words: piperacillin Piperacillin PIPC PIPC g g PIPC Cmax g g ml g g ml g g ml T T T PIPC g g T Ccr ml min AUCCmax PIPC
Clostridium difficile ciprofloxacin, ofloxacin, norfloxacin Bifidobacterium Lactobacillus Lactobacillus Bacteroides fragilis B. fragilis C. difficile
Clostridium difficile ciprofloxacin, ofloxacin, norfloxacin Bifidobacterium Lactobacillus Lactobacillus Bacteroides fragilis B. fragilis C. difficile Key words: temafloxacin, TA-167, Bacteroides fragilis,
2.7.6 MJR a MRI CT b 2 Beecham r-afs mg/ mg/ Gn-RH 742
MJR-35 34 1 1 a MRICT b 2Beecham r-afs 3 4 20 4 mg/ 20 40 5 6 2 1 2 3 44 mg/ 5 6 7 8 4 Gn-RH 742 9 10 11 12 1 20 60 1 1MJR-351 mg/ 0.25 2 Lot. No. 2MJR-352 mg/ 1 1 Lot. No. 3MJR-354 mg/ 1 2 Lot. No. 2
CHEMOTHERAPY
CHEMOTHERAPY CHEMOTHERAPY Table 1 Antibacterial activity of Sulbactam/CPZ against standard strains MIC mg/ml Inoculum size 106 CFU/ml * Sulbactam/CPZ= 1: 1 ** Concentration of Sulbactam+ CPZ CHEMOTHERAPY
164 SDD & SOD SDD E100 mg 80 mg B500 mg 2 E 2 B 48 /59 81 SDD SOD 10 /63 16 RCT RCT 1992 Gastinne 15 ICU 445 SDD E100 mg 80 mg B 10
163 特 集 SDD & SOD SDD(Selective digestive decontamination),sod(selective oropharynx decontamination), 腸内細菌叢, 耐性菌 Ⅰ はじめに SDD Selective digestive decontamination SOD Selective oropharynx decontamination
THE JAPANESE JOURNAL OF ANTIBIOTICS 65 2 Apr non-albicans 4 non-albicans C. glabrata, C. parapsilosis, C. tropicalis, C. krusei 4 C. guil
Apr. 2012 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 2 111 13 B ACTIONs Bundle ACTIONs Bundle 2009 7 ACTIONs Bundle ACTIONs project Appropriate Candidal Treatment, Implementation Of Nonneutropenic strategies
Table 1 Patients with various renal function * Ccr, Creatinine clearance ml/min per 1. 48 m2 ** C.V.D., Cerebral vascular disease ; C.R F., Chronic renal failure ; H.D., Hemoclialysis ; D., Dialyzer ;
_02三浦.indd
36, 7-11, 2016 IPD PCV 5 3 80% 1 invasive pneumococcal disease ; IPD 2010 7 PCV7 2013 13 PCV13 IPD IPD 2,3 2015 1 2015 12 5 1 IPD 2015 1 12 IPD 5 IPD 1 4 2 5 http://pneumocatch.jp/ 5 Statens Serum Institut
Rinku General Medical Center
Rinku General Medical Center 4860 100 1620 Ann Intern Med. 1966; 64: 328 40 CHOP 63 1 83 J Clin Oncol. 1998; 16: 20065-69 Febrile Neutropenia IDSA(Infectious Diseases Society of America) 2002 Guidelines
Oct THE JAPANESE JOURNAL OF ANTIBIOTICS Pseudomonas aeruginosa 186 P. aeruginosa piperacillin PIPC, taz
Oct. 2016 THE JAPANESE JOURNAL OF ANTIBIOTICS 69 5 327 27 2013 2014 2016 7 5 2013 2014 Pseudomonas aeruginosa 186 P. aeruginosa piperacillin PIPC, tazobactam/piperacillin TAZ/PIPC, ceftazidime CAZ, cefepime
387 ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( )
386 B B () () ( ) ( ) ( ) 387 ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) 388 ( ) ( ) ( ) 389 ( ) 2 ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) 390 ( ) ( ) ( ) () () ( ) Hot flush 391 ( ) ( ) ( ) 392 ( ( )
Table 1.Resistance criteria Fig.1.The resistance rates of piperacillin,ceftazidime, cefsulodin,imipenem,aztreonam,gentamicin,tobramycin,amikacin,isepamicin,fosfomycin and ofloxacin against 2,793 strains
1.8.2 Page MIC () MIC 50 / MIC 90 µg/ml Candida albicans (54) / Candida glabrata (25) 0.25 / 0.5 Candida guilliermondii a) (2)
1.8.2 Page1 1.8.2 96% 2002 40 B 1 123 (1) in vitro 1) in vitro C. glabrata C. krusei 1 2 19951997 3 1999 2002 MIC MIC 2 1.8.2 Page2 1 19951997 MIC () MIC 50 / MIC 90 µg/ml Candida albicans (54) 0.016 /
366 12 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 Dec. 2012 1 8 DNA 2,3 16 12 20 171 2008 12 2010 11 2 3,558 4.44% 1.65% 1.17% 90% 9 Escherichia coli -
Dec. 2012 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 365 11 sita oxacin 1 1 1 1 1 1 2 2 3 3 1 1 1 2 3 2012 9 14 sita oxacin STFX 50 mg 10% 2008 1 2008 12 2010 11 2 STFX 1,452 91.4% 1,235/1,351 95.9% 466/486
VOL. 40 S- 1 Table 1. Susceptibility of methicillin-resistant Staphylococcus aureus to meropenem Table 2. Coagulase typing of methicillin-resistant St
CHEMOTHERAPY VOL. 40 S- 1 Table 1. Susceptibility of methicillin-resistant Staphylococcus aureus to meropenem Table 2. Coagulase typing of methicillin-resistant Staphylococcus aureus CHEMOTHERAPY Table
日本化学療法学会雑誌第61巻第6号
β Moraxella catarrhalis Escherichia coli Citrobacter Klebsiella pneumoniae Enterobacter cloacae Serratia marcescens Proteus Pseudomonas aeruginosa Acinetobacter Bacteroides fragilis β Haemophilus influenzae
10 : 3010 : 54 1F Annex 1! 1 15:3015 : 58 1F Annex 1
4 16 1 10:0010 : 24 1F Annex 1! 2 15:0015 : 24 1F Annex 1!! 10 : 3010 : 54 1F Annex 1! 1 15:3015 : 58 1F Annex 1 ! 2 10:0010 : 28 1F Annex 1 3 15:0015 : 28 1F Annex 1 4 10:3010 : 58 1F Annex 1 1 15:3015
2 129-B*-006P 129-B*-007P C*-004P 129-D*-001P ADH B*-006P B*-007P C*-004P D*-001P Na
2.7.4 2.7.4.1 2.7.4.1.1 11 ADH 1 ADH 1 4 7 129-A*-003 129-B*-001 129-E*-001P 129-G*-001 129-H*-002 129-H*-004 129-H*-005 132 242 4 129-B*-004 129-C*-005P 129-H*-003 129-H*-006 44 ADH ADH 129-C*-001P 16
152273335 1 123 11531 2 5 24 31 2 154301482 1551 JAS 100 2000 105 1101 1 2JAS 1-2 1
152273335 1 123 11531 2 5 24 31 2 154301482 1551 JAS 100 2000 105 1101 1 2JAS 1-2 1 JAS 1-2 1-2 112 13 1-11-13 100870mg 100830mg11000 1100020.002 2 50 100 2 100 500 2 100 109252165 4514782 7 2.0kg 2-19220.05kg0.2kg
CHEMOTHERAPY FEB Table 1. Activity of cefpirome and others against clinical isolates
VOL.39 S-1 CHEMOTHERAPY FEB. 1981 Table 1. Activity of cefpirome and others against clinical isolates VOL.39 S-1 CHEMOTHERAPY FEB. 1991 72 M, 55.5 kg 66 F, 53 kg Chronic bronchitis Bronchopneumonia Peak
Key words: E. coli O 157: H7, fosfomycin, verotoxin, mouse infection
Key words: E. coli O 157: H7, fosfomycin, verotoxin, mouse infection Table 1. Bacterial cell counts in feces of mice infected with Esclwrichia coli O 157: H7 NK2 before and during oral dosing with fosfomycin
200mg 2005 3 876179 2002 3 3 200mg VFEND for Intravenous Use (1) (2) [4.1 ] (3) [4.2 ] (1) [1] (2) (3) [1] 3
E Societe de Pathologie Infectieuse de Langue Francaise (, 1991) E Spanish Thoracic Society (1992) E American Thoracic Society (ATS : 1993. ü ù2001 ) E British Thoracic Society (1993, ü è2001 ) E Canadian
Table 1.Concentration of gatifloxacin (Middle-ear) Table 2.Concentration of gatifloxacin (Paranasal sinuses) Table 3.Concentration of gatifloxacin (Tonsil) Table 4.No.of patients studied Table 5.Background
Table 1 Sensitivity distribution of clinical isolates 1. Escherichia coli Inoculum size: 106cells/ml 2. Klebsiella pneumoniae 3. Enterobacter cloacae 4. Serratia marcescens Inoculum size: 106cells/nil
VOL.32 S-7 CHEMOTHERAPY Table 1 MIC of standard strains of CTRX Fig. 2 Cumulative curves of MIC S. aureus (26 strains )
CHEMOTHERAPY OCT. 1984 Fig. I Chemical structure of CTRX VOL.32 S-7 CHEMOTHERAPY Table 1 MIC of standard strains of CTRX Fig. 2 Cumulative curves of MIC S. aureus (26 strains ) CHEMOTHERAPY Fig. 3 Cumulative
20mg #tr#5*xlj lffin&+'.':, t) r+'z)vt '+D#J Centers for Medicare & Medicaid Sewices Garden AS et al. Preliminary results ofradiation Therapy Oncology Group 97-03: a randomized phase II trial of
O1-1 O1-2 O1-3 O1-4 O1-5 O1-6
O1-1 O1-2 O1-3 O1-4 O1-5 O1-6 O1-7 O1-8 O1-9 O1-10 O1-11 O1-12 O1-13 O1-14 O1-15 O1-16 O1-17 O1-18 O1-19 O1-20 O1-21 O1-22 O1-23 O1-24 O1-25 O1-26 O1-27 O1-28 O1-29 O1-30 O1-31 O1-32 O1-33 O1-34 O1-35
CHEMOTHERAPY JUN Citrobacter freundii 27, Enterobacter aerogenes 26, Enterobacter cloacae 27, Proteus rettgeri 7, Proteus inconstans 20, Proteus
VOL. 32 S-4 CHEMOTHERAPY Fig. 1 Chemical structure of sodium cefoperazone Fig. 2 Chemical structure of sodium cefoperazone CHEMOTHERAPY JUN. 1984 Citrobacter freundii 27, Enterobacter aerogenes 26, Enterobacter
日歯雑誌（Ｈ２８・８月号）別刷り／ポスターセッション とびら
α P. gingivalis P. gingivalis αsmatgf- VEGF-A α in vitro μ Porphyromonas gingivalis in vitro Porphyromonas gingivalis β β β JBiolChem. μ μ μ β Porphyromonas gingivalis in vitro μ α β α
CHEMOTHERAPY JUNE 1993 Table 1. Background of patients in pharmacokinetic study
CHEMOTHERAPY JUNE 1993 Table 1. Background of patients in pharmacokinetic study VOL. 41 S 1 Table 2. Levels (Đg/ml or Đg/g) of S-1006 in serum, bile, and tissue (gallbladder) after oral administration
coccus aureus Corynebacterium sp, Haemophilus parainfluenzae Klebsiella pneumoniae Pseudornonas aeruginosa Pseudomonas sp., Xanthomonas maltophilia, F
VOL.43 S-1 coccus aureus Corynebacterium sp, Haemophilus parainfluenzae Klebsiella pneumoniae Pseudornonas aeruginosa Pseudomonas sp., Xanthomonas maltophilia, Flavobacter- Table 1. Concentration of grepafloxacin
第86回日本感染症学会総会学術集会後抄録（I）
κ κ κ κ κ κ μ μ β β β γ α α β β γ α β α α α γ α β β γ μ β β μ μ α ββ β β β β β β β β β β β β β β β β β β γ β μ μ μ μμ μ μ μ μ β β μ μ μ μ μ μ μ μ μ μ μ μ μ μ β
CHEMOTHERAPY APRIL 1992 Acinetobacter calcoaceticus Staphylococcus aureus, Escherichia coli P. aeruginosa E. eoli, Klebsiella pneumoniae Serratia marc
APRIL 1992 Acinetobacter calcoaceticus Staphylococcus aureus, Escherichia coli P. aeruginosa E. eoli, Klebsiella pneumoniae Serratia marcescens P. aeruginosa P. aeruginosa Streptococcus pyogenes Streptococcus
CHEMOTHERAPY APRIL 1992 VOL. 40 S- 1 Table 1-1. Comparative in vitro activity of meropenem against clinical isolates CNS: coagulase-negative staphylococci CHEMOTHERAPY APRIL 1992 Table 1-2. Comparative
1) 1) 1 R 2 3 4 5 6 3) 4) 5) Punch 7 10g/mL(63.6mol/L) 20mg/kg 78 5 23 Cmax 250mg 3.9g/ml 500mg 6.0g/ml1000mg 8g/ml2000mg 15g/ml 33.4 110-116mL/min 1,8) 8 95 9 10 ( ) 11 desa 12 13 12) 2.5 5 19 Rec assayames
Staphylococcus sp. K.pneumoniae P.mirabilis C.freundii E. cloacae Serratia sp. P. aeruginosa ml, Enterococcus avium >100ƒÊg/ml
CHEMOTHERAPY SEPT. 1992 cefoperazone ceftazidime (CAZ), imipenem (IPM) Staphylococcus sp., Enterococcus (CPZ), faecalis, Escherichia coli, Klebsiella pneumoniae, Citrobacter freundii, Enterobacter cloacae,
THE JAPANESE JOURNAL OF ANTIBIOTICS 68 3 June 2015 Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis % 2 S. pneumon
June 2015 THE JAPANESE JOURNAL OF ANTIBIOTICS 68 3 189 49 1 : 14 1 2 2 3 1 2 3 2015 4 3 1 : 14 CVA/AMPC 1 : 14 27 CVA/AMPC 1 : 14 88.5% Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis
untitled
20 2 14 18 10 16 1 1.0mg 0.035mg 2 1 20 2 14 18 10 16 1 1 1 52 1 1 21 7 28 1 29 2 1 20 1 24 18 10 16 1 1 21 7 28 1 29 1 NET 1.0mg EE 0.035mg *NET *NET 1999 2007 *NET *NET 88 NSAIDs GnRH GnRH NSAIDs 20
1 911 9001030 9:00 A B C D E F G H I J K L M 1A0900 1B0900 1C0900 1D0900 1E0900 1F0900 1G0900 1H0900 1I0900 1J0900 1K0900 1L0900 1M0900 9:15 1A0915 1B0915 1C0915 1D0915 1E0915 1F0915 1G0915 1H0915 1I0915
1 23G 2 1 2 3 4 5 6 7 3 a a b c a 4 1 18G 18G 6 6 3 30 34 2 23G 48 23G 1 25 45 5 20 145mm 20 26 0.6 1.000 0.7 1.000mm a b c a 20 b c 24 28 a c d 3 60 70 / a RC 5 15 b 1 3 c 0.5 1 4 6 5 a 5 1 b a b a d
日本化学療法学会雑誌第57巻第4号
Streptococcus pneumoniae Haemophilus influenzae β β Key words I β Enterococcus faecium Pseudomonas aeruginosa Streptococcus pneumoniae S. pneumoniae Haemophilus influenzae S. pneumoniae H. influenzae Table.
CHEMOTHERAPY aureus 0.10, Enterococcus faecalis 3.13, Escherichia coli 0.20, Klebsiella pneumoniae, Enterobacter spp., Serratia marcescens 0.78, Prote
aureus 0.10, Enterococcus faecalis 3.13, Escherichia coli 0.20, Klebsiella pneumoniae, Enterobacter spp., Serratia marcescens 0.78, Proteus mirabilis 3.13, Proteus vulgaris 1.56, Citrobacter freundii 0.39,
THE JAPANESE JOURNAL OF ANTIBIOTICS 67 3 June 2014 azithromycin AZM, 500 mg 37.0 C communityacquired pneumonia; CAP C C-reactive protein; CRP 9
June 2014 THE JAPANESE JOURNAL OF ANTIBIOTICS 67 3 193 47 1 1 1 1 3 3 4 1 5 6 1 2 5 5 1 2 4 1 6 1 3 7 2 1 1 2 3 4 5 6 7 2014 4 14 azithromycin; AZM 15 community-acquired pneumonia; CAP AZM A-DROP CAP AZM
02-(a)-Łi’ì™·Łv-4.11
THE JAPANESE JOURNAL OF ANTIBIOTICS 56 2 105( 13 ) 2001 1) 2) 3) JA 2 7 1) 2) 3) 106( 14 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 56 2 Apr. 1982 7 2001 (2001.4 2002.3) 1 221 175 (79.2%) 420 186 234 Staphylococcus
デスフルラン
デスフルラン時代の周術期管理 岡山大学麻酔科蘇生科森松博史 デスフルランの特徴!!! 岡山大学での現状 本日のお話 デスフルランの特徴 3 Eger et al. Anesth Analg 1998; 86: 414-21 デスフルランの特徴 2 つのメタアナリシス 2005 Macario et al. Am J Health Syst Pharm!! 2010 Dexter et al.
日本化学療法学会雑誌第57巻第6号
Streptococcus pneumoniae Haemophilus influenzae Moraxella catarrhalis S. pneumoniae S. pneumoniae β β H. influenzae S. pneumoniae H. influenzae M. catarrhalis Key words Otalgia Fever Item Crying,Iritation,
VOL.35 S-2 CHEMOTHERAPY Table 1 Sex and age distribution Table 2 Applications of treatment with carumonam Table 3 Concentration of carumonam in human
CHEMOTHERAPY Fig. 1 Chemical structure of carumonam Disodium(+)-(Z)-CCE1-(2-amino-4-thiazoly1)-2-[[(2S, -(carbamoyloxymethyl)-4-oxo-1-sulfonato-3-azetidinyll -2-oxoethylidene] amino] oxy] acetate 3S)-2
untitled
Seminal paper Anhalt JP Pioneering paper Claydon MA Kishnamurthy T Enterobacter B. cereus Routine identification paper Eigner U Seng P Cherkaoui A Saureus S. Saureus* S. Vagococcus Haemophilus Mycobacterium
家庭系パソコンの回収再資源化にかかる論点
1 134 1212 134 2 1 137 1212 (1) 12 12,102 40.2 4,865 2-1 12 21,497 2-2 50.1 2-3 1 kg 2 12 2-1 13 12% 2-1 (2) 2-2 4 4 7 2-3 4 (3) 13.8 2-4 46 10 80 3 3 4 3 2-5, 2-6 13 9 2-7 18 2 2 8 5,000 30 25% 25 2 2
CHEMOTHERAPY NOV S. aureus, S. epidermidis, E. coli, K. pgeumoniae, E. cloacae, S. marcescens, P. mirabilis, Proteus, P. aeruginosa Inoculum siz
VOL.33 S-5 CHEMOTHERAPY 381 Fig. 1 Chemical structure of HAPA-B Chemical name 1-N-[(2S)-3-Amino-2-hydroxypropiony1]-4-0-(6-amino- 6-deoxy-a-D-glucopyranosyl)-6-013-deoxy-4-C-methyl- 3-(methylamino)-ƒÀ-L-arabinopyranosyl]-2-deoxystreptamine
THE JAPANESE JOURNAL OF ANTIBIOTICS 57 1 33( 33 ) 2002 JA * 1 * 2 2003 12 15 * 1) * 2) 34( 34 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 57 1 Feb. 1982 7 2002 (2002.4 2003.3) 1 174 131 (75.3%) 334 171 163 Staphylococcus
BUN, CRP K mg/ cm, 49.6 kg, BMI /72 mmhg, 92/ Hb 6.7 g/dl PT-INR CT 1 MRI 2a, b T1 T2 T1 MRI
20 2 2015 1 2 3 85 K CT Abstract A case of renal subcapsular hematoma resulting from trigger point injection under excessive effect of anticoagulant YAMANE Tateki, UMEDA Akira and SHIMAO Hitoshi An 85-year-old
FCシリンダ
CAT. No. KS-570-01 C ujikura cylinder INDEX Page CS - - -22 CS - -3 - CD - -3 - CS -40-0 -4 CD -40-0 -4 CS - -20-3 CD - -20-3 CL-400 VCS CDR -400 1 ujikura Cylinders 2 3 4 C 0 3 0.0.7 00 CD 0 4 S0 P CS
70( 70 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 57 1 Feb. Meropenem 2002 * * * * * * * * * * * * * * * * * * * * * * NTT Feb. THE JAPANESE JOURNAL OF ANTIBIOTICS 57 1 71( 71 ) * * * * 2003 12 22 Meropenem
CTD 2 2.6 5.3mg 0.4mg 0.6mg 0.8mg 1.0mg 1.2mg 1.4mg 1.6mg 1.8mg 2.0mg 12mg 2.6 Page 3 2.6.6...5 2.6.6.1...6 2.6.6.2...9 2.6.6.3...9 2.6.6.4... 11 2.6.6.5... 11 2.6.6.6... 11 2.6.6.7... 11 2.6.6.8... 11
The clinical characteristics of Mycoplasma pneumoniae pneumonia in children younger than 6 years old Nobue Takeda1,2),Tomomichi Kurosaki1),Naruhiko Ishiwada2),Yoichi Kohno2) 1)Department of Pediatrics,Chiba
トキコストッパルブレーキパッド適合表ホンダ 型式排気量グレード年式フロントリア CR-V RD AT 車 95.10~01.08 XH496M ドラム RD MT 車 95.10~01.08 XH266M ドラム RD AT 車 98.12~01.08 XH496
CR-V RD1 2000 AT 車 95.10~01.08 XH496M ドラム RD1 2000 MT 車 95.10~01.08 XH266M ドラム RD2 2000 AT 車 98.12~01.08 XH496M ドラム RD4 2000 01.09~04.09 XH654M XH710M RD5 2000 MT,AT(VSA 無 )( 形状確認 ) 01.09~04.09 XH654M
Fig. 1 Chemical structure of TE-031 Code number: TE-031 Chemical name: (-) (3R, 4S, 5S, 6R, 7R, 9R, 11R, 12R, 13S, 14R)-4-[(2, 6-dideoxy-3-C-methyl-3-
Fig. 1 Chemical structure of TE-031 Code number: TE-031 Chemical name: (-) (3R, 4S, 5S, 6R, 7R, 9R, 11R, 12R, 13S, 14R)-4-[(2, 6-dideoxy-3-C-methyl-3-O-methyl-a-L-ribo-hexopyranosyl) oxy]-14-ethyl-12,
36 th IChO : - 3 ( ) , G O O D L U C K final 1
36 th ICh - - 5 - - : - 3 ( ) - 169 - -, - - - - - - - G D L U C K final 1 1 1.01 2 e 4.00 3 Li 6.94 4 Be 9.01 5 B 10.81 6 C 12.01 7 N 14.01 8 16.00 9 F 19.00 10 Ne 20.18 11 Na 22.99 12 Mg 24.31 Periodic
ｎｓｇ０２－１３／ｋｙ０４５０５９３０１６０００３３２１０
φ φ φ φ κ κ α α μ μ α α μ χ et al Neurosci. Res. Trpv J Physiol μ μ α α α β in vivo β β β β β β β β in vitro β γ μ δ μδ δ δ α θ α θ α In Biomechanics at Micro- and Nanoscale Levels, Volume I W W v W
(1.2) T D = 0 T = D = 30 kn 1.2 (1.4) 2F W = 0 F = W/2 = 300 kn/2 = 150 kn 1.3 (1.9) R = W 1 + W 2 = = 1100 N. (1.9) W 2 b W 1 a = 0
1 1 1.1 1.) T D = T = D = kn 1. 1.4) F W = F = W/ = kn/ = 15 kn 1. 1.9) R = W 1 + W = 6 + 5 = 11 N. 1.9) W b W 1 a = a = W /W 1 )b = 5/6) = 5 cm 1.4 AB AC P 1, P x, y x, y y x 1.4.) P sin 6 + P 1 sin 45
橡
TP T-13i AST ALT ALP Y CTP LOH CHE CRP 8.7 id 0.4 mg/d 21 AWL 131U/L 257 LU/L 12 111/L 234 11J/L 344 IU/L 0.30 mid No K a BUN ORE UA 142 meq/1 4.3 meqa 108 meqa 15.8 met! 0.71 mg/di 5.0 mg/d CEA 5_5 n8/m1
日本化学療法学会雑誌第53巻第S-1号
Doripenem in vitro Doripenem in vitro 7 7 3 DRPM in vitro DRPM 00 DRPM Staphylococcus Streptococcus µ gml MIC90 Moraxella catarrhalishaemophilus influenzae µ gml MIC90 imipenem IPM panipenem meropenemmepm
untitled
1988 2000 2002 2004 2006 2008 IFN Lamivudine Adefovir Entecavir 1 Total number 560 Sex (male/female) 424/136 Age (years)* 38 (15-68) Duration of treatment (weeks)* 26 (1-592) Follow-up time (years) 75(05-21
untitled
ORYZA OIL & FAT CHEMICAL CO., LTD. WHITE JELLY FUNGUS EXTRACT -P () Ver. 1.3SJ Ver. 1.3SJ 1. 3000 ph 1 Ver. 1.3SJ 1. 1 2. 3 2-1. 2-2. 2-3. 2-4. SOD 3. 7 3-1. in vitro 3-2. in vivo 3-3. in vivo 3-4. in
CHEMOTHERAPY FEB Table 1 Background of volunteers
CHEMOTHERAPY FEB. 1985 Table 1 Background of volunteers Table 3 Reproducibility of saisomicln In the EIA and the RIA Fig.1 Comparison of the EIA with the RIA or bioassay of sisomicin Table 4 Blood levels
第65回日本化学療法学会東日本支部総会 抄録
鍵 76 Clostridioides difficile C. difficile 77 γ γ Mycobacterium avium 78 79 Clostridium difficile Treponema pallidum 80 81 82 in vitro in vitro 83 鍵 Treponema pallidum 84 Chlamydia trachomatis Mycoplasma
32 1 BRONJ BRONJ II BRONJ BRONJ 4 BP BRONJ 6 1 III BP BRONJ
29 1 31 40 2014 31 Bisphosphonate related osteonecrosis of jaw; BRONJ 2008 4 2012 3 36 98 8 11 19 BRONJ 0 13 2 5 3 1 1 0 BP 4 15 10 5 α-streptococcus 0 BRONJ BRONJ BP I Paget 1 409-3898 1110 2014 1 27
epidermidis, Enterococcus faecalis, Enterococcus Klebsiella pneumoniae, Proteus mirabilis, indolepositive Proteus spp., Enterobacter spp., Serratia
epidermidis, Enterococcus faecalis, Enterococcus Klebsiella pneumoniae, Proteus mirabilis, indolepositive Proteus spp., Enterobacter spp., Serratia Table 3. Overall clinical efficacy of cefozopran in